Brief: Mainz Biomed: Presents Groundbreaking Results Of Colofuture Study
18/10/2023 13:02
Oct 18 (Reuters) - Mainz Biomed Nv 4TO.F :
* PRESENTS GROUNDBREAKING RESULTS OF COLOFUTURE STUDY
* RESULTS INDICATE A SUBSTANTIAL AND MEANINGFUL ENHANCEMENT
IN
EFFECTIVENESS OF NON-INVASIVE COLORECTAL CANCER (CRC) SCREENING,
PARTICULARLY FOR DETECTION OF ADVANCED ADENOMAS, A PRECURSOR TO
CRC
* CLINICAL TRIAL EVALUATING COMPANY'S NOVEL MRNA BIOMARKERS
DEMONSTRATED SENSITIVITY FOR COLORECTAL CANCER OF 94% WITH
SPECIFICITY OF 97% AND ADVANCED ADENOMA SENSITIVITY OF 80%
Source text for Eikon: ID:nEQ3hpWXLa
Further company coverage: 4TO.F
(Reporting by Berlin Newsroom)
((berlin.newsroom@thomsonreuters.com;))
Recent news on Quantum Cyber NV
See all newsBrief: Quantum Cyber To Proceed With Pending Litigation Against Adam Gefvert
Brief: Quantum Cyber NV Files Lawsuit Against White Diamond Research, Adam Gefvert And Stocktwits, Inc. In New York Supreme Court
Quantum Cyber jumps on SpaceX stake purchase plan
Brief: Quantum Cyber Signs Loi To Acquire An Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility To Support Mass-Scale Autonomous Drone Production
Brief: Quantum Cyber NV - To Terminate ATM Sales Agreement With Maxim Effective June 7, 2026 - SEC Filing